Medicilon(SH:688202) Shang Hai Zheng Quan Bao·2025-09-04 20:05Group 1: Shareholder Equity Change Announcement - The company received a notice from shareholder Lin Changqing regarding a reduction in shareholding, with a total of 950,000 shares sold, representing 0.71% of the total share capital as of September 3, 2025 [1][2] - Following the reduction, Lin Changqing's shareholding decreased from 5,473,654 shares (4.07%) to 4,523,654 shares (3.37%), while the combined holdings of Lin and his associate Chen Guoxing fell from 10,348,808 shares (7.70%) to 9,398,808 shares (7.00%) [1][2] - The reduction in shareholding does not trigger a mandatory tender offer and will not change the company's controlling shareholder or actual controller [2] Group 2: Litigation Involving Subsidiary - The company's wholly-owned subsidiary, MediXipia Pharmaceutical Technology (Shanghai) Co., Ltd., is a defendant in a lawsuit initiated by Hongxu Biological Technology (Beijing) Co., Ltd. regarding a technical service contract dispute [4][5] - The lawsuit, which has been filed but not yet heard, involves a claim amounting to approximately 158.53 million yuan, while the contract amount in question is 5.58 million yuan [5][8] - The company asserts that it has fulfilled its contractual obligations and plans to actively defend against the claims, including potential counterclaims against Hongxu Biological [5][10]